ATE386942T1 - Verfahren zur voraussage, zur diagnose und zur vergleichenden diagnose von alzheimer - Google Patents

Verfahren zur voraussage, zur diagnose und zur vergleichenden diagnose von alzheimer

Info

Publication number
ATE386942T1
ATE386942T1 AT04730881T AT04730881T ATE386942T1 AT E386942 T1 ATE386942 T1 AT E386942T1 AT 04730881 T AT04730881 T AT 04730881T AT 04730881 T AT04730881 T AT 04730881T AT E386942 T1 ATE386942 T1 AT E386942T1
Authority
AT
Austria
Prior art keywords
diagnosis
alzheimer
disease
prediction
comparative
Prior art date
Application number
AT04730881T
Other languages
English (en)
Inventor
Hugo Vanderstichele
Eugeen Vanmechelen
Kaj Blennow
Meyer Geert De
Vesna Kostanjevecki
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Application granted granted Critical
Publication of ATE386942T1 publication Critical patent/ATE386942T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
AT04730881T 2003-05-22 2004-05-03 Verfahren zur voraussage, zur diagnose und zur vergleichenden diagnose von alzheimer ATE386942T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03447120A EP1480041A1 (de) 2003-05-22 2003-05-22 Verfahren zur Voraussage, zur Diagnose und zur vergleichenden Diagnose von Alzheimer
US47762103P 2003-06-11 2003-06-11

Publications (1)

Publication Number Publication Date
ATE386942T1 true ATE386942T1 (de) 2008-03-15

Family

ID=33041166

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04730881T ATE386942T1 (de) 2003-05-22 2004-05-03 Verfahren zur voraussage, zur diagnose und zur vergleichenden diagnose von alzheimer

Country Status (14)

Country Link
US (2) US20040265919A1 (de)
EP (2) EP1480041A1 (de)
JP (1) JP4769722B2 (de)
AT (1) ATE386942T1 (de)
AU (1) AU2004242203B2 (de)
CA (1) CA2525781C (de)
CY (1) CY1110252T1 (de)
DE (1) DE602004011931T2 (de)
DK (1) DK1625403T3 (de)
ES (1) ES2301986T3 (de)
PL (1) PL1625403T3 (de)
PT (1) PT1625403E (de)
SI (1) SI1625403T1 (de)
WO (1) WO2004104597A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
WO2006014723A2 (en) * 2004-07-19 2006-02-09 Mayo Foundation For Medical Education And Research Predicting alzheimer's disease
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
EP1838348B1 (de) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
EP1959996A2 (de) 2005-12-12 2008-08-27 AC Immune S.A. Monoklonaler antikörper
JP4790013B2 (ja) * 2006-04-13 2011-10-12 エーディア株式会社 β−アミロイドの血中分解速度測定によるアルツハイマー病の検定に用いられる方法及び診断試薬
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
EP2046833B9 (de) 2006-07-14 2014-02-19 AC Immune S.A. Humanisierter antikörper gegen amyloid beta
WO2008058760A1 (en) * 2006-11-17 2008-05-22 Friedrich-Alexander-Universität Erlangen-Nürnberg Method of differentially diagnosing dementias
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009095454A2 (de) * 2008-02-01 2009-08-06 Brahms Aktiengesellschaft Verfahren zur identifizierung von therapiebedürftigen patienten mit leichten kognitiven störungen und die behandlung derartiger patienten
WO2010009987A2 (en) * 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
EP2344881A4 (de) * 2008-09-26 2012-03-07 Univ Melbourne Biomarker für morbus alzheimer
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2011033046A1 (en) * 2009-09-18 2011-03-24 Probiodrug Ag Novel assay for the detection of amyloid beta peptides
BR112012014060B8 (pt) * 2009-12-11 2021-07-27 Araclon Biotech Sl método para o diagnóstico da doença de alzheimer em um sujeito, para detecção da disfunção cognitiva branda ou para diferenciar a doença de alzheimer da disfunção cognitiva branda
DE102010014684A1 (de) * 2010-04-09 2011-10-13 Universität Duisburg-Essen Neue Ansätze zur Alzheimer-Diagnose
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2598882B1 (de) 2010-07-30 2017-07-26 AC Immune S.A. Sichere und funktionelle humanisierte antikörper für die verwendung in der behandlung von einer amyloidose
EP3533803B1 (de) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antikörper
EP2511296A1 (de) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antikörper, Kit und Verfahren zur Bestimmung von Amyloidpeptiden
JP6231263B2 (ja) * 2012-07-17 2017-11-15 株式会社島津製作所 アフィニティ支持体及びそれを用いた物質の捕捉方法
NZ630542A (en) 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
US10304006B2 (en) * 2013-02-15 2019-05-28 The Charles Stark Draper Laboratory, Inc. Method for integrating and fusing heterogeneous data types to perform predictive analysis
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
US20180252665A1 (en) * 2014-05-27 2018-09-06 Case Western Reserve University System and methods for the detection of biomarkers of neurodegenerative disorders
EP3149486A1 (de) * 2014-05-30 2017-04-05 Biocross, S.L. Verfahren zur diagnose von morbus alzheimer und milder kognitiver beeinträchtigung
EP2950102A1 (de) * 2014-05-30 2015-12-02 Biocross, S.L. Verfahren zur Diagnose von Morbus Alzheimer und milder kognitiver Beeinträchtigung
CN113884683A (zh) * 2020-07-30 2022-01-04 山东京济生物工程有限公司 一种快速检测Aβ42的双抗体夹心ELISA试剂盒
US20220260559A1 (en) * 2020-11-04 2022-08-18 Seer, Inc. Biomarkers for diagnosing alzheimer's disease
JP2024514049A (ja) * 2021-03-16 2024-03-28 ニューロビジョン イメージング， インコーポレイテッド アルツハイマー病関連状態を診断するための生物流体ベースの方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
ATE239797T1 (de) * 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
CA2306501C (en) * 1997-10-14 2011-03-29 Luminex Corporation Precision fluorescently dyed particles and methods of making and using same
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20020182660A1 (en) * 2000-02-18 2002-12-05 Fong Kei-Lai L. N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43)
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
ATE277952T1 (de) * 2001-06-12 2004-10-15 Wiltfang Jens Monoklonaler antikörper, mbab 1e8, welcher für die zwei ersten n-terminalen aminosäuren von amyloid-beta-peptiden spezifisch ist und dessen verwendung zum nachweis von amyloid-beta peptiden und/oder sappa
PT1416965E (pt) * 2001-08-17 2008-04-01 Lilly Co Eli Método de ensaio para a doença de alzheimer

Also Published As

Publication number Publication date
EP1625403A1 (de) 2006-02-15
PT1625403E (pt) 2008-05-28
PL1625403T3 (pl) 2008-10-31
AU2004242203B2 (en) 2008-12-11
AU2004242203A1 (en) 2004-12-02
ES2301986T3 (es) 2008-07-01
CA2525781A1 (en) 2004-12-02
CY1110252T1 (el) 2015-01-14
CA2525781C (en) 2013-08-13
SI1625403T1 (sl) 2008-08-31
JP2007522434A (ja) 2007-08-09
DE602004011931D1 (de) 2008-04-03
US20040265919A1 (en) 2004-12-30
JP4769722B2 (ja) 2011-09-07
WO2004104597A1 (en) 2004-12-02
EP1480041A1 (de) 2004-11-24
DK1625403T3 (da) 2008-06-09
US20080057593A1 (en) 2008-03-06
EP1625403B1 (de) 2008-02-20
DE602004011931T2 (de) 2009-09-10

Similar Documents

Publication Publication Date Title
ATE386942T1 (de) Verfahren zur voraussage, zur diagnose und zur vergleichenden diagnose von alzheimer
ATE283485T1 (de) Verfahren zur diagnose und zur charakterisierung von schlaganfall
WO2004001421A3 (en) Method for the diagnosis and differential diagnosis of neurological diseases
DE60109311D1 (de) Kit zur simultanen diagnose mehrerer ansteckender krankheiten und verfahren zu seiner herstellung
WO2005061545A3 (en) Nogoa antibodies for the treatment of alzheimer disease
BR0111125A (pt) Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos
ATE409047T1 (de) Humanisierte antikörper
DE60239522D1 (de) Verfahren zur behandlung von autoimmunerkrankungen bei einem probanden und diagnostische in-vitro-assays
DE60333608D1 (de) Biomarker zur Diagnose von Alzheimer
DE10295664D2 (de) Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Paptide und deren Verwendungen
ATE404118T1 (de) System für kontinuierliche leistungstests
AU2003259222A1 (en) Method of diagnosing alzheimer's disease
Neugroschl et al. Biological markers in Alzheimer disease
DE60322768D1 (de) Verfahren zur Herstellung von Partikeln für ein diagnostisches Reagenz
DE602004026683D1 (de) Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins
WO2001020533A3 (en) Creation of a database of biochemical data and methods of use
ATE275268T1 (de) Verfahren zur diagnose von sjögren-syndrom
ATE347698T1 (de) Verfahren zum nachweis von alzheimer-krankheit
ATE393785T1 (de) Glykopeptide, deren herstellung und verwendung in der diagnose oder behandlung von multipler sklerose
IL175004A0 (en) Quick test for the diagnosis of alzheimer's disease
ATE518005T1 (de) Verfahren zur diagnose und prognose von morbus alzheimer
DE60235576D1 (de) Diagnostikum für die frühe phase von morbus alzheimer
DE602004024992D1 (de) Verwendung von pyrazolopyridinen zur behandlung von kognitiven defiziten
ATE360094T1 (de) Tcf-1 nukleotidsequenzvariation
AU2003236714A8 (en) Diagnosis of alzheimer's disease based on the habeta42:habeta40 ratio

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1625403

Country of ref document: EP